These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 20002538)
41. Thrombin generation in vitro and in vivo, and disturbed tissue factor regulation in patients with acute pancreatitis. Lindström OK; Tukiainen EM; Kylänpää ML; Mentula PJ; Puolakkainen PA; Wartiovaara-Kautto UM; Repo H; Petäjä JM Pancreatology; 2011; 11(6):557-66. PubMed ID: 22213026 [TBL] [Abstract][Full Text] [Related]
42. Regulation of thrombin generation by TFPI in plasma without and with heparin. Brodin E; Appelbom H; Osterud B; Hilden I; Petersen LC; Hansen JB Transl Res; 2009 Mar; 153(3):124-31. PubMed ID: 19218095 [TBL] [Abstract][Full Text] [Related]
43. Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity. MacDonald S; White D; Langdown J; Downes K; Thomas W Int J Lab Hematol; 2020 Jun; 42(3):246-255. PubMed ID: 32003946 [TBL] [Abstract][Full Text] [Related]
44. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI. Erem C; Nuhoglu I; Kocak M; Yilmaz M; Sipahi ST; Ucuncu O; Ersoz HO Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004 [TBL] [Abstract][Full Text] [Related]
45. Effects of oral contraceptives on hemostasis and thrombosis. Rosing J; Tans G Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524 [TBL] [Abstract][Full Text] [Related]
46. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Dahm A; Van Hylckama Vlieg A; Bendz B; Rosendaal F; Bertina RM; Sandset PM Blood; 2003 Jun; 101(11):4387-92. PubMed ID: 12560220 [TBL] [Abstract][Full Text] [Related]
47. Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia. Tchaikovski SN; Thomassen MC; Costa SD; Peeters LL; Rosing J Thromb Haemost; 2011 Nov; 106(5):914-21. PubMed ID: 21979881 [TBL] [Abstract][Full Text] [Related]
48. Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels. Agledahl I; Brodin E; Svartberg J; Hansen JB Thromb Haemost; 2009 Nov; 102(5):945-50. PubMed ID: 19888533 [TBL] [Abstract][Full Text] [Related]
49. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Raps M; Helmerhorst FM; Fleischer K; Dahm AE; Rosendaal FR; Rosing J; Reitsma P; Sandset PM; van Vliet HA Thromb Haemost; 2013 Apr; 109(4):606-13. PubMed ID: 23407778 [TBL] [Abstract][Full Text] [Related]
50. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism. Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu İ; Ersoz HO Endocrine; 2009 Dec; 36(3):473-8. PubMed ID: 19859836 [TBL] [Abstract][Full Text] [Related]
51. Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition. Undas A; Gissel M; Kwasny-Krochin B; Gluszko P; Mann KG; Brummel-Ziedins KE Thromb Haemost; 2010 Aug; 104(2):224-30. PubMed ID: 20593110 [TBL] [Abstract][Full Text] [Related]
52. Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting. Kopp CW; Steiner S; Priglinger U; Christ G; Probst P; Maurer G; Minar E; Huber K Blood Coagul Fibrinolysis; 2003 Jun; 14(4):379-86. PubMed ID: 12945880 [TBL] [Abstract][Full Text] [Related]
53. High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. Ariëns RA; Moia M; Rivolta E; Ponticelli C; Mannucci PM Thromb Haemost; 1999 Sep; 82(3):1020-3. PubMed ID: 10494757 [TBL] [Abstract][Full Text] [Related]
55. Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism. Dennis J; Truong V; Aïssi D; Medina-Rivera A; Blankenberg S; Germain M; Lemire M; Antounians L; Civelek M; Schnabel R; Wells P; Wilson MD; Morange PE; Trégouët DA; Gagnon F J Thromb Haemost; 2016 Oct; 14(10):1960-1970. PubMed ID: 27490645 [TBL] [Abstract][Full Text] [Related]
56. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. Ahnström J; Andersson HM; Hockey V; Meng Y; McKinnon TA; Hamuro T; Crawley JT; Lane DA Blood; 2012 Dec; 120(25):5059-62. PubMed ID: 23074276 [TBL] [Abstract][Full Text] [Related]
57. Decreased anticoagulant response to tissue factor pathway inhibitor in patients with venous thromboembolism and otherwise no evidence of hereditary or acquired thrombophilia. Bombeli T; Piccapietra B; Boersma J; Fehr J Thromb Haemost; 2004 Jan; 91(1):80-6. PubMed ID: 14691572 [TBL] [Abstract][Full Text] [Related]
58. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus. Leurs PB; van Oerle R; Wolffenbuttel BH; Hamulyak K Thromb Haemost; 1997 Mar; 77(3):472-6. PubMed ID: 9065996 [TBL] [Abstract][Full Text] [Related]
59. The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography. Audu P; Nielsen VG; Armstead V; Powell G; Kim J; Kim L; Mehta M Anesth Analg; 2006 Oct; 103(4):841-5. PubMed ID: 17000790 [TBL] [Abstract][Full Text] [Related]